# Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)

> **NCT00116935** · PHASE3 · COMPLETED · sponsor: **Scandinavian Sarcoma Group** · enrollment: 400 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** imatinib mesylate
- **DRUG:** imatinib
- **DRUG:** imatinib

## Key facts

- **NCT ID:** NCT00116935
- **Lead sponsor:** Scandinavian Sarcoma Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2011-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116935, "Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00116935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*